Vu00ecrus of parainfluenza, methods for stimulating the immune system of a patient to induce protection against vu00ecrus of parainfluenza and to produce a partu00eccula of vu00ecrus of parainfluenza.The method of sequential immunization to stimulate the immune system of a patient to induce protection against multiple pathogens.Immunogenic composition to evoke an immune response against the virus of parainfluenza, polinucleotu00ecdeo isolated and vector of expression

摘要

"Vu00ecrus of parainfluenza, methods for stimulating the immune system of a patient to induce protection against vu00ecrus of parainfluenza and to produce a partu00eccula of vu00ecrus of parainfluenza.The method of sequential immunization to stimulate the immune system of a patient to induce protection against multiple pathogens.Immunogenic composition to evoke an immune response against the vu00ecrus of parainfluenza, polinucleotu00ecdeo isolated and vector for expression.Chimeric parainfluenza viruses (PIVS) are provided which incorporate a PIV vector genome or antigenoma and one or more antigenic determinants of a pathogen PIV or heterologous PIV.These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations to evoke an immune response against one or more PIVS or against pathogens P.IV and PIV.Also provided are isolated polynucleotides encoding molecules and vectors that incorporate a genome or antigenoma of chimeric PIV genome or antigenoma that include a vector of partial or complete PIVCombined or integrated with one or more genes heteru00f3logos or segments of the genome which encode antigenic determinants of a pathogen PIV or heterologous PIV.In preferred aspects of the invention, chimeric PIV genome or antigenoma incorporates a vector of PIV, partial or complete, humans.Bovine or human bovine chimeric combined with one or more genes heteru00f3logos or segments of the genome of a heterologous PIV pathogen of PIV or not.In the chimeric virus is attenuated for use as an agent of the vaccine by any of a variety of mutations and nucleotide changes introduced in the genome or antigenoma chimeric.